Page 15 - Leon Wang News Today : Breaking News, Live Updates & Top Stories | Vimarsana

The United Kingdom-based pharmaceutical giant AstraZeneca is stepping up efforts to coordinate its development strategy with China's national agendas.

Huawei named a 2020 Gartner Peer Insights Customers’ Choice for Data Center and Cloud Networking Huawei, a leading global provider of information and communications technology (ICT) infrastructure and smart devices, is excited to share that they were named a 2020 Gartner Peer Insights Customers’ Choice for Data Center and Cloud Networking for its CloudFabric Data Center Network (DCN) Solution. Huawei has a high 4.9/5 stars as of November 2020, ranking first among almost 20 vendors. As of November 2020, Huawei CloudFabric has received customer feedback from ...

Operator Good morning to those joining from the U.K. and the U.S. Good afternoon to those in Central Europe. Welcome, ladies and gentlemen, to AstraZeneca's full-year 2020 results conference call and webcast for investors and analysts. Before I hand it over to AstraZeneca, I'd like to read the safe harbor statement. The company intends to utilize the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Participants on this call may make forward-looking statements with respect to the operations and financial performance of AstraZeneca. Although we belie...

Article content BEIJING — China’s Shenzhen Kangtai Biological Products said on Tuesday it had completed a facility designed to be able to produce 400 million doses of AstraZeneca’s COVID-19 vaccine per year, doubling a capacity target promised in 2020. “Kangtai is actively pushing forward procedures for the vaccine’s clinical trial and registration in China, and has completed a manufacturing plant and started trial production,” the Shenzhen-based firm said in a press release. We apologize, but this video has failed to load. Try refreshing your browser, or AstraZeneca's China part...

COVID-19 vaccine: AstraZeneca's China partner expects to produce 400 million doses a year The firm obtained rights to supply the AZD1222 vaccine, developed by the Anglo-Swedish drugmaker and Oxford University, in mainland China last year in return for having capacity to produce at least 200 million doses by the end of 2021 Reuters | February 2, 2021 | Updated 14:49 IST China's Shenzhen Kangtai Biological Products said on Tuesday it had completed a facility designed to be able to produce 400 million doses of AstraZeneca's COVID-19 vaccine per year, doubling a capacity target promised in 2020....